A PROPENSITY SCORE-BASED COMPARISON OF TEPOTINIB VERSUS IMMUNOTHERAPY WITH/WITHOUT CHEMOTHERAPY, USING REAL-WORLD DATA IN PREVIOUSLY UNTREATED MET EXON 14 (METEX14) SKIPPING NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Hook, E. [1 ]
Batteson, R. [2 ]
Christopoulos, P. [3 ,4 ,5 ]
Guisier, F. [6 ,7 ]
Ekman, S. [8 ]
Hatswell, A.
Vioix, H. [9 ]
机构：
[1] Delta Hat Ltd, Nottingham, NGM, England
[2] Delta Hat Ltd, Nottingham, England
[3] Heidelberg Univ Hosp, Thoraxklin, Heidelberg, Germany
[4] Heidelberg Univ Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany
[5] German Ctr Lung Res DZL, Translat Lung Res Ctr Heidelberg TLRC H, Heidelberg, Germany
[6] Univ Rouen Normandie, Dept Pneumol, LITIS Lab QuantIF team EA4108, CHU Rouen, F-76000 Rouen, France
[7] Inserm CIC CRB 1404, F-76000 Rouen, France
[8] Karolinska Univ Hospital, Dept Oncol Pathol, Karolinska Inst, Stockholm, Sweden
[9] Merck Healthcare KGaA, Darmstadt, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO168
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 50 条
  • [41] Characterization of MET exon 14 skipping in Chinese non-small cell lung cancer (NSCLC) patients.
    Zhang, Baihua
    Xia, Yu
    Zhang, Jiujin
    Yu, Jin
    Chen, Min
    Yao, Wei
    Zhao, Juan
    He, Jiqiang
    Mok, Tony S. K.
    Wang, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Clinical outcomes in advanced Non-Small Cell Lung Cancer (NSCLC) with MET exon 14 skipping mutation
    Smith, Miles
    Carter, Mat
    Woodhouse, Laura
    Adderley, Helen
    Morrissey, George
    Brown, Kate
    Nicola, Pantelis
    Weaver, Jamie
    Califano, Raffaele
    Summers, Yvonne
    Cove-Smith, Laura
    Hughes, Sarah
    Taylor, Paul
    Blackhall, Fiona
    Lindsay, Colin R.
    LUNG CANCER, 2024, 190
  • [43] Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report
    Chen, Zhuxing
    Zhu, Feng
    Li, Caichen
    Li, Jianfu
    Cheng, Bo
    Xiong, Shan
    Zhong, Ran
    Liang, Wenhua
    He, Jianxing
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (05)
  • [44] Immunotherapy for stage IV non-small cell lung cancer patients with MET exon 14 skipping mutation
    Kuon, J.
    Blasi, M.
    Shah, R.
    Christopoulos, P.
    Stenzinger, A.
    Kazdal, D.
    Herth, F. J.
    Heussel, C. P.
    Thomas, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 172 - 172
  • [45] Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United States
    Stargardter, Matthew
    McBride, Ali
    Tosh, Jon
    Sachdev, Rameet
    Yang, Mo
    Ambavane, Apoorva
    Mittal, Madhav
    Vioix, Helene
    Liu, Frank Xiaoqing
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 816 - 827
  • [46] MET exon 14 skipping mutations in advanced non-small cell lung cancer (NSCLC) are not associated with MET amplification and overexpression
    Gimenez-Capitan, Ana
    Teixido, Cristina
    Aguado, Cristina
    Rodriguez, Sonia
    Bertran-Alamillo, Jordi
    Castellvi, Josep
    Yeste, Zaira
    Perez, Ana
    Rosell, Rafael
    Molina-Vila, Miguel Angel
    CANCER RESEARCH, 2017, 77
  • [47] An Efficacy Analysis of Advanced Non Small Cell Lung Cancer With MET Exon 14 Skipping in the Real World
    Teng, F.
    Xing, P.
    Hao, X.
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S472 - S472
  • [48] Tepotinib in Non-Small Cell Lung Cancer with MET Exon 14-Skipping Mutations or MET Amplification: a Phase 2 Trial in Progress
    Paik, P.
    Sakai, H.
    Bruns, R.
    Scheele, J.
    Straub, J.
    Felip, E.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1046 - S1046
  • [49] Real-world experience with capmatinib in MET exon 14 mutated non-small cell lung cancer (RECAP)
    Illini, Oliver
    Fabikan, Hannah
    Swalduz, Aurelie
    Vikstrom, Anders
    Krenbek, Dagmar
    Schumacher, Michael
    Dudnik, Elizabeth
    Studnicka, Michael
    Ohman, Ronny
    Wurm, Robert
    Wannesson, Luciano
    Peled, Nir
    Kian, Waleed
    Bar, Jair
    Daher, Sameh
    Addeo, Alfredo
    Rotem, Ofer
    Pall, Georg
    Zer, Alona
    Saad, Akram
    Cufer, Tanja
    Sorotsky, Hadas Gantz
    Hashemi, Sayed M. S. .
    Mohorcic, Katja
    Stoff, Ronen
    Rovitsky, Yulia
    Keren-Rosenberg, Shoshana
    Winder, Thomas
    Weinlinger, Christoph
    Valipour, Arschang
    Hochmair, Maximilian J.
    WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (19-20) : 726 - 727
  • [50] Financial impact of tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer bearing METex14 skipping in the United States.
    Stargardter, Matthew
    Yang, Mo
    Tosh, Jon
    Ambavane, Apoorva
    Mittal, Madhav
    Vioix, Helene
    Liu, Frank Xiaoqing
    McBride, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345